Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00402883 · ClinicalTrials.gov registry record · Phase 2
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
A Phase 2 study, sponsored by SCRI Development Innovations.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00402883 is a Phase 2 study that was terminated before completion, run by SCRI Development Innovations. The registered enrollment target is 5 participants.
The verdict
NCT00402883, a Phase 2 study, was terminated before completion, sponsored by SCRI Development Innovations.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.
Interventions
- DRUG Bevacizumab
- DRUG Pemetrexed
- PROCEDURE Radiotherapy
- OTHER Folic Acid
- OTHER vitamin B12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2006-11 |
| Est. Completion | 2009-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00402883
The ClinicalTrials.gov registry entry for NCT00402883 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Bevacizumab is the first listed.
NCT00402883 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00402883 about?
NCT00402883 is a clinical study titled "Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer". The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.
What is the current status of trial NCT00402883?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2006-11. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00402883?
The interventions under investigation include: Bevacizumab (DRUG), Pemetrexed (DRUG), Radiotherapy (PROCEDURE), Folic Acid (OTHER), vitamin B12 (OTHER).
Who is sponsoring clinical trial NCT00402883?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.